발생일자 2015.02.18 

사건번호 2:15-cv-01283 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.NewJersey(지방법원) 

침해권리 특허 

원고명 Novartis Vaccines and Diagnostics, Inc./ Novartis Pharma AG ( 미국 / 외국기업 )  

피고명 Pfizer, Inc. ( 미국 / 외국기업 )  

소송유형 침해금지 

[Novartis Vaccines and Diagnostics, Inc. et al v. Pfizer, Inc.] 사건번호 2:15-cv-01283에 따르면 원고 Novartis Vaccines and Diagnostics, Inc./ Novartis Pharma AG는 피고 Pfizer, Inc.을 상대로 특허 US7576176, US8394390, US8398988, US8524251, US8834888, US8840907 을 침해하였다는 이유로 미국 뉴저지 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Bivalent rLP2086 vaccine 

지재권번호/명칭

US7576176   Neisseria meningitidis antigens and compositions 

US8394390   Neisserial antigenic peptides 

US8398988   Adjuvanting meningococcal factor H binding protein 

US8524251   Neisseria meningitidis antigens and compositions 

US8834888   Adjuvanting meningococcal factor H binding protein 

US8840907   Isolated protein and compositions comprising the protein 

The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics. 

 1. A purified polypeptide comprising a fragment of an amino acid sequence of SEQ ID NO: 2536, wherein said fragment comprises 10 or more consecutive amino acids from said amino acid sequence. 

 2. The purified polypeptide of claim 1, wherein said fragment comprises 12 or more consecutive amino acids from said amino acid sequence. 

 3. The purified polypeptide of claim 1, wherein said fragment comprises 14 or more consecutive amino acids from said amino acid sequence. 

 4. The purified polypeptide of claim 1, wherein said fragment comprises 16 or more consecutive amino acids from said amino acid sequence. 

 5. The purified polypeptide of claim 1, wherein said fragment comprises 18 or more consecutive amino acids from said amino acid sequence. 

 6. The purified polypeptide of claim 1, wherein said fragment comprises 20 or more consecutive amino acids from said amino acid sequence. 

 7. The purified polypeptide of claim 1 further comprising a pharmaceutically acceptable carrier. 

 8. The purified polypeptide of claim 1, wherein the purified polypeptide is immunogenic. 

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids. 

 1. A purified polypeptide comprising a fragment of an amino acid sequence of SEQ ID NO: 2536, wherein said fragment comprises 10 or more consecutive amino acids from said amino acid sequence. 

 2. The purified polypeptide of claim 1, wherein said fragment comprises 12 or more consecutive amino acids from said amino acid sequence. 

 3. The purified polypeptide of claim 1, wherein said fragment comprises 14 or more consecutive amino acids from said amino acid sequence. 

 4. The purified polypeptide of claim 1, wherein said fragment comprises 16 or more consecutive amino acids from said amino acid sequence. 

 5. The purified polypeptide of claim 1, wherein said fragment comprises 18 or more consecutive amino acids from said amino acid sequence. 

 6. The purified polypeptide of claim 1, wherein said fragment comprises 20 or more consecutive amino acids from said amino acid sequence. 

 7. The purified polypeptide of claim 1 further comprising a pharmaceutically acceptable carrier. 

 8. The purified polypeptide of claim 1, wherein the purified polypeptide is immunogenic.